Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

5(55.6%)

Phase 2

3(33.3%)

N/A

1(11.1%)

9Total

Phase 3(5)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00276640Not ApplicableCompleted

Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas

Role: lead

NCT00003859Phase 3Completed

Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS

Role: lead

NCT00025428Phase 3Completed

Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma

Role: lead

NCT00002898Phase 3Completed

Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma

Role: lead

NCT00025441Phase 2Completed

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Role: lead

NCT00003015Phase 3Unknown

Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma

Role: lead

NCT00003912Phase 3Completed

Chemotherapy in Treating Children With Liver Cancer

Role: lead

NCT00003122Phase 2Unknown

Surgery in Treating Patients With Neuroblastoma

Role: lead

NCT00004224Phase 2Completed

Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma

Role: lead

All 9 trials loaded